The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), has been awarded a $799,735 grant by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant, titled "Tissue Perfusion Pressure for Improved Management of Circulatory Shock", aims to develop a novel hemodynamic metric called Tissue Perfusion Pressure (TPP) to guide the treatment of circulatory shock in critically ill patients. Over the 4-year project period from July 2024 to May 2028, the researchers will investigate the physiology of TPP in preclinical animal models, analyze clinical data to identify patterns in TPP response, and develop a computational pipeline for real-time TPP analysis to support clinical decision making. If successful, this project will advance TPP as a potential therapeutic target for the diagnosis and management of circulatory shock, laying the groundwork for future clinical trials.
Generated 2/25/25, 3:52 AM